Balyasny Asset Management
SPPI

Balyasny Asset Management’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Balyasny Asset Management’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,000
Closed -$1.03M – 1857
2018
Q3 		$1.03M Buy
+50,000
New +$1.08M ﹤0.01% 1170

Other funds holding SPPI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's SPPI Position: Q3 2022 in Review

Balyasny Asset Management sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2022, closing a stake of 29,524 shares — an estimated $23K sold.

Balyasny Asset Management first reported a position in SPPI in Q2 2013 and held it in 12 quarters. The position peaked at $10.6M in Q4 2017. 75 funds tracked by Wall St. Rank hold SPPI as of Q3 2022.

  • Balyasny Asset Management reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 29,524 Spectrum Pharmaceuticals Inc shares in Q3 2022, an estimated $23K.
  • Balyasny Asset Management first reported a position in Spectrum Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
  • Balyasny Asset Management's Spectrum Pharmaceuticals Inc position peaked at $10.6M in Q4 2017.
  • 75 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.